New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
10:01 EDTWTS, SRPT, NAT, HOMB, ATHN, UMC, SB, MS, HNI, ZMH, TWC, PLXS, HUBG, CMG, BIG, AIV, BXP, AVIV, DYN, BWP, ACIOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Aimco (AIV) upgraded to Equalweight from Underweight at Barclays... Arch Coal (ACI) upgraded to Neutral from Sell at Goldman... Aviv REIT (AVIV) upgraded to Buy from Neutral at Goldman... Big Lots (BIG) upgraded to Overweight from Neutral at Piper Jaffray... Boardwalk Pipeline (BWP) upgraded to Outperform from Sector Perform at RBC Capital... Boston Properties (BXP) upgraded to Outperform from Market Perform at Cowen... Chipotle (CMG) upgraded to Overweight from Neutral at JPMorgan... Dynegy (DYN) upgraded to Buy from Neutral at UBS... HNI Corporation (HNI) upgraded to Outperform from Market Perform at Raymond James... Home Bancshares (HOMB) upgraded to Outperform from Market Perform at Raymond James... Hub Group (HUBG) upgraded to Buy from Neutral at Longbow... Morgan Stanley (MS) upgraded to Buy from Neutral at Nomura... Nordic American Tanker (NAT) upgraded to Hold from Underperform at Jefferies... Plexus (PLXS) upgraded at Needham... Safe Bulkers (SB) upgraded to Buy from Hold at Jefferies... Sarepta (SRPT) upgraded to Outperform from Market Perform at William Blair... Time Warner Cable (TWC) upgraded to Buy from Hold at Brean Capital... United Microelectronics (UMC) upgraded to Neutral from Sell at Goldman...Watts Water (WTS) upgraded at Oppenheimer... Zimmer (ZMH) upgraded to Buy from Hold at Cantor... athenahealth (ATHN) upgraded to Hold from Underperform at Jefferies.
News For AIV;ACI;AVIV;BIG;BWP;BXP;CMG;DYN;HNI;HOMB;HUBG;MS;NAT;PLXS;SB;SRPT;TWC;UMC;WTS;ZMH;ATHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
August 24, 2015
09:03 EDTCMGChipotle price target raised to $740 from $620 at Wedbush
Subscribe for More Information
09:00 EDTCMGChipotle to hire 4,000 people on a single day on September 9
Subscribe for More Information
06:50 EDTSRPTSarepta upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information
06:36 EDTCMGChipotle to hire 4,000 employees in one day next month, WSJ reports
Subscribe for More Information
August 21, 2015
17:29 EDTDYNPJM releases results for 2018-2019 PJM Interconnection capacity auction
Subscribe for More Information
10:36 EDTSRPTOptions with increasing implied volatility
Options with increasing implied volatility: PTCT UVXY VIX VXX SVXXY SRPT TZA UPRO VNR SPXU
08:40 EDTMSCanadian Security Traders Association to hold a conference
Subscribe for More Information
08:32 EDTSRPTSarepta says FDA grants rare pediatric disease designation for Eteplirsen
Subscribe for More Information
05:28 EDTNATNordic American Tankers CEO, family increase holding in NAT by 100K shares
Subscribe for More Information
August 20, 2015
11:49 EDTSRPTOptions with increasing implied volatility
Options with increasing implied volatility: SRPT ACHN VIAV ZG RAD DIS ORCL SPY XLF OEX
06:10 EDTMSWeather Channel said to hire banks to explore sale, Bloomberg reports
Subscribe for More Information
06:07 EDTMSSamsung Bioepis picks Citi, Goldman as lead managers for IPO, Reuters says
Samsung Bioepis has selected Citigroup (C) and Goldman Sachs (GS) as the lead managers for its planned listening on Nasdaq next year, a source tells Reuters. Morgan Stanley (MS) and Credit Suisse (CS) will also take part in the listing for Samsung's (SSNLF) biosimilar drug development arm, the source says. Reference Link
August 19, 2015
14:42 EDTMSBanks cooperate on data company to lower costs, WSJ says
Subscribe for More Information
10:20 EDTTWCBig telecom firms put M&A on hold, CTFN reports
Subscribe for More Information
10:00 EDTCMGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Biocept (BIOC) initiated with a Buy at H.C. Wainwright... C.H. Robinson (CHRW) initiated with a Buy at Evercore ISI... Chipotle (CMG) initiated with a Hold at Maxim... Con-way (CNW) initiated with a Buy at Evercore ISI... Dermira (DERM) initiated with an Outperform at Cowen... Expeditors (EXPD) initiated with a Hold at Evercore ISI... Fleetmatics (FLTX) initiated with an In-Line at Imperial Capital... Frontier Communications (FTR) initiated with an Overweight at Stephens... Gevo (GEVO) initiated with a Buy at Rodman & Renshaw... International Game (IGT) initiated with a Sell at Goldman... Knight Transportation (KNX) initiated with a Buy at Evercore ISI... Logitech (LOGI) initiated with a Buy at Rosenblatt... Navistar (NAV) initiated with a Neutral at Macquarie... Panera Bread (PNRA) initiated with a Hold at Maxim... Scientific Games (SGMS) initiated with a Sell at Goldman... Swift Transport (SWFT) initiated with a Hold at Evercore ISI... Tribune Media (TRCO) initiated with an Equal Weight at Morgan Stanley... WEX Inc. (WEX) initiated with an Equal Weight at Barclays... Zoe's Kitchen (ZOES) initiated with a Buy at Maxim.
09:17 EDTSRPT'Female Viagra' approval seen as positive for Sarepta, BioMarin
The FDA's approval of the world's first drug designed to boost a woman's sexual desire is seen as boding well for companies awaiting critical decisions by the agency. FEMALE VIAGRA: The Food and Drug Administration yesterday approved flibanserin to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. The drug, which will be sold under the name "Addyi" and is commonly referred to as the "female Viagra," is the first FDA-approved treatment for sexual desire disorders in men or women, the agency prominently stated in its press release. HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance, the FDA explained. Addyi was approved with a risk evaluation and mitigation strategy as well as a Boxed Warning given the risk of severe hypotension and syncope in patients who drink alcohol during treatment. The drug is made by privately held Sprout Pharmaceuticals. ANALYST REACTION: Addyi's approval is "another sign of flexibility" by the FDA, especially for first-in-class therapies, Roth Capital analyst Debjit Chattopadhyay writes this morning in a note to investors. This bodes well for the approval of eteplirsen, drisapersen and Translarna, the analyst contends. Eteplirsen, designed by Sarepta Therapeutics (SRPT), and drisapersen, designed by BioMarin (BMRN), are experimental drugs being developed to treat Duchenne muscular dystrophy. Translarna, designed by PTC Therapeutics (PTCT), is already being sold in Europe as a treatment for DMD and is awaiting approval from the FDA. Duchenne muscular dystrophy is a form of muscular dystrophy affecting around 1 in 3,600 boys, which results in muscle degeneration and premature death. SAVING LIVES: While female sexual dysfunction is a clinical problem, eteplirsen is designed to save lives, Chattopadhyay points out. He has a Buy rating on Sarepta and noted his price target of $45 assumes accelerated approval for eteplirsen in the first quarter of 2016. Shares of the Massachusetts-based biopharmaceutical company closed yesterday at $35.69.
08:29 EDTSRPTFlibanserin approval bodes well for Sarepta, others, says Roth Capital
Subscribe for More Information
August 18, 2015
18:52 EDTCMGChipotle initiated with a Hold at Maxim
Subscribe for More Information
10:17 EDTTWCDisney downgraded as Wells moves away from content providers
Subscribe for More Information
06:16 EDTCMGFast food chains making new push with more fresh ingredients, WSJ says
Subscribe for More Information
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use